Stevanato Group Market Research Report

Background

Company Overview

Stevanato Group S.p.A., founded in 1949 by Giovanni Stevanato in Venice, Italy, is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in the design, production, and distribution of glass and plastic primary packaging, as well as related machinery and services. Headquartered in Piombino Dese, Padua, Italy, Stevanato Group operates worldwide, serving over 70 countries.

Mission and Vision

Stevanato Group's mission is to provide integrated solutions that enhance the safety, efficacy, and efficiency of pharmaceutical products. The company's vision is to be a trusted partner in the pharmaceutical and healthcare industries, delivering innovative and high-quality solutions across the entire drug lifecycle.

Industry Significance

As a pioneer in glass primary packaging, Stevanato Group holds a significant position in the pharmaceutical packaging industry. The company's products are integral to the delivery of injectable medications, ensuring sterility, stability, and patient safety. Stevanato Group's expertise in both manufacturing and machinery design allows it to offer comprehensive solutions to its clients.

Key Strategic Focus

Core Objectives

Innovation: Continuously invest in research and development to create advanced drug containment and delivery systems.

Global Expansion: Strengthen its global presence through strategic acquisitions and the establishment of new manufacturing facilities.

Customer Integration: Provide end-to-end solutions that integrate seamlessly into clients' operations, enhancing efficiency and reducing time-to-market.

Areas of Specialization

Glass Primary Packaging: Production of vials, syringes, and cartridges for injectable drugs.

Drug Delivery Systems: Development of pen injectors, auto-injectors, and wearable devices.

Engineering Solutions: Design and manufacturing of machinery for glass forming, inspection, assembly, and packaging.

Key Technologies Utilized

EZ-fill® Technology: Pre-sterilized, ready-to-fill glass containers that reduce contamination risks and streamline the filling process.

SG Alina® Pen Injector Platform: A customizable pen injector platform for various drug formulations.

SG EZ-be Pod® Wearable Injector: An on-body delivery system for biologics and other injectable medications.

Primary Markets Targeted

Biopharmaceuticals: Including biologics and biosimilars.

Vaccines: Ensuring safe and efficient delivery.

Diagnostics: Providing solutions for in-vitro diagnostic products.

Financials and Funding

Funding History

Stevanato Group went public on the New York Stock Exchange on July 16, 2021, under the ticker symbol STVN. The IPO raised approximately $672 million, valuing the company at nearly $7 billion at that time.

Recent Financial Performance

In 2024, Stevanato Group reported net sales of €1.104 billion, reflecting a compound annual growth rate (CAGR) of 15.5% from 2019 to 2024.

Utilization of Capital

The funds raised from the IPO have been allocated to:

Expansion of Manufacturing Facilities: Including new plants in Cisterna di Latina (Italy) and Fishers (Indiana, USA).

Research and Development: Enhancing product innovation and technological advancements.

Strategic Acquisitions: Strengthening capabilities in drug delivery systems and diagnostics.

Pipeline Development

Key Pipeline Candidates

SG Alina® Pen Injector Platform: A customizable pen injector platform for various drug formulations.

SG EZ-be Pod® Wearable Injector: An on-body delivery system for biologics and other injectable medications.

Stages of Development

SG Alina® Pen Injector Platform: Currently in the commercialization phase, with adoption by multiple pharmaceutical companies.

SG EZ-be Pod® Wearable Injector: Undergoing clinical trials, with expected market introduction in the next 1-2 years.

Target Conditions

SG Alina® Pen Injector Platform: Designed for chronic conditions requiring regular injections, such as diabetes and rheumatoid arthritis.

SG EZ-be Pod® Wearable Injector: Intended for biologics and other injectable medications, including vaccines and monoclonal antibodies.

Anticipated Milestones

SG Alina® Pen Injector Platform: Achieved CE marking and FDA clearance; currently in use by several clients.

SG EZ-be Pod® Wearable Injector: Expected to complete clinical trials by mid-2026, with market launch anticipated in late 2026.

Technological Platform and Innovation

Proprietary Technologies

EZ-fill® Technology: Pre-sterilized, ready-to-fill glass containers that reduce contamination risks and streamline the filling process.

SG Alina® Pen Injector Platform: A customizable pen injector platform for various drug formulations.

SG EZ-be Pod® Wearable Injector: An on-body delivery system for biologics and other injectable medications.

Significant Scientific Methods

Analytical Testing Services: Container closure integrity testing, extractables and leachables studies, and other laboratory services.

Vision Inspection Systems: Automated systems for quality control in pharmaceutical packaging.

Leadership Team

Executive Profiles

Franco Stevanato: Executive Chairman and CEO. Franco resumed his role as CEO in May 2024, having previously served as Executive Chairman and CEO from 2010 to 2020. He holds a bachelor's degree in political science from the University of Trieste and completed the advanced management program at the Kellogg School of Management at Northwestern University.

Marco Dal Lago: Chief Financial Officer. Marco brings over 25 years of experience in finance and administration. He joined Stevanato Group in 2020 and leads the global finance, controlling, tax, information technology, legal, and administrative teams. He graduated with a bachelor's degree in business administration from Ca’ Foscari University of Venice and completed the advanced management program at MIT in Boston.

Mauro Stocchi: Chief Business Strategy Officer. With more than 25 years of business development experience, Mauro joined Stevanato Group in 2004 and has held various key management positions. He currently oversees all strategic business development activities, including sales, product management, corporate development, strategic marketing, and supply chain management. He earned a master’s degree in business administration from SDA Bocconi in Milan and holds a bachelor's degree from Ca’ Foscari University of Venice.

Lisa Miles: Chief Communications and Investor Relations Officer. Lisa joined Stevanato Group in 2021 and assumed her current role in 2024. She is responsible for the Group’s global communications, media, and brand strategy, as well as the investor relations function. Previously, she spent 18 years at Maximus in various management positions, including Senior Vice President of Investor Relations & Corporate Communications. She holds a bachelor’s degree in communications from The Pennsylvania State University and completed an executive leadership program at Harvard Business School.

Carla Costa: Chief Human Resources Officer. Carla joined Stevanato Group in 2024 and was appointed Chief Human Resources Officer in April 2025. She leads the Group’s global human resources strategy. With more than 20 years of industry experience, Carla has held strategic roles across multiple industries and geographies, implementing people strategies that drive business success. She holds a degree in organizational psychology from the Università Cattolica of Milan.

Ugo Gay: President, DCS Business Unit and Shared Services. Ugo joined Stevanato Group in 2024 as Chief Operations Officer and was appointed President of the Drug Containment Solutions Business Unit and Shared Services in 2025. He leads the Group’s operational and growth strategy. Ugo holds a degree from the SDA Bocconi School of Management in Milan.

Raffaele Pace: President, Engineering Business Unit. Raffaele joined Stevanato Group in 2020 as Vice President, Operations for the Engineering Segment and was appointed President of the Engineering Business Unit in 2025. He has over 20 years of international experience in the engineering, packaging, and pharmaceutical sectors. Raffaele holds a master’s degree in mechanical engineering and an MBA from Bologna Business School.

Michele Monico: President, DDS and IVD Business Unit. Michele joined Stevanato Group in 2023 as Vice President of the Drug Delivery

stevanato-group